Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
Department of Food and Nutrition, Kyung Hee University, Seoul, South Korea.
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1891-1901. doi: 10.1158/1055-9965.EPI-19-0156. Epub 2019 Aug 9.
Although an association between alcohol consumption and risk of colorectal cancer is well established, little is known about the association between alcohol consumption and colorectal cancer survival. We conducted a meta-analysis of prospective cohort studies to quantitatively assess this association.
Data searches were performed using PubMed and ISI Web of Science databases through December 2018. We estimated pooled RRs with 95% confidence intervals (CI) using random-effects models.
Twelve studies with 32,846 patients with colorectal cancer were included in the meta-analysis. Compared with no alcohol consumption, light (RR = 0.87; 95% CI, 0.81-0.94) and moderate (RR = 0.92; 95% CI, 0.85-1.00) prediagnostic alcohol consumption were associated with lower risk of all-cause mortality. Light prediagnostic alcohol consumption was associated with lower risk of colorectal cancer-specific mortality (RR = 0.87; 95% CI, 0.78-0.98). However, heavy prediagnostic alcohol consumption was not significantly associated with colorectal cancer survival. In a dose-response analysis, a nonlinear association between prediagnostic alcohol consumption and all-cause mortality was observed ( = 0.0025), showing the reduction in RR at <30 g/day of alcohol consumption. By type of alcohol, wine consumption was associated with lower risk of mortality from all-causes and colorectal cancer, but a positive association was observed between moderate liquor consumption and all-cause mortality. There was no association between postdiagnostic alcohol consumption and colorectal cancer survival.
Light and moderate prediagnostic alcohol consumption were associated with better survival in colorectal cancer.
Our findings suggest that light and moderate alcohol consumption may be associated with better survival in colorectal cancer, but further studies are warranted.
尽管饮酒与结直肠癌风险之间存在关联已得到充分证实，但对于饮酒与结直肠癌生存之间的关联知之甚少。我们进行了一项荟萃分析，以定量评估这种关联。
通过PubMed 和 ISI Web of Science 数据库进行数据检索，检索时间截至 2018 年 12 月。我们使用随机效应模型估计汇总 RR 和 95%置信区间（CI）。
共有 12 项研究纳入了 32846 例结直肠癌患者，总计 32846 例结直肠癌患者，进行了荟萃分析。与不饮酒相比，轻（RR = 0.87；95%CI，0.81-0.94）和中度（RR = 0.92；95%CI，0.85-1.00）的预诊断饮酒与全因死亡率降低相关。轻量预诊断饮酒与结直肠癌特异性死亡率降低相关（RR = 0.87；95%CI，0.78-0.98）。然而，大量预诊断饮酒与结直肠癌的生存无显著相关性。在剂量反应分析中，观察到预诊断饮酒与全因死亡率之间存在非线性关联（ = 0.0025），表明在酒精摄入量<30 g/天的情况下，RR 降低。按酒的种类来看，饮酒与全因死亡率和结直肠癌死亡率降低有关，但中度白酒消费与全因死亡率呈正相关。诊断后饮酒与结直肠癌的生存无关联。
轻量和中量预诊断饮酒与结直肠癌的生存改善有关。
我们的研究结果表明，轻量和中度饮酒可能与结直肠癌的生存改善有关，但需要进一步的研究。
